Ginkgo biloba and risk of cancer: secondary analysis of the Ginkgo Evaluation of Memory (GEM) Study
Ginkgo biloba and risk of cancer: secondary analysis of the Ginkgo Evaluation of Memory (GEM) Study
复制标题
DOI：
10.1002/pds.1979
复制
发表时间：
2010-07-01
影响因子：
2.6
通讯作者：
Fitzpatrick, Annette L.
中科院分区：
文献类型：
--
作者：
Biggs, Mary L.;Sorkin, Barbara C.;Fitzpatrick, Annette L.
目的体外和体内研究的证据表明银杏具有癌症化学预防作用，但流行病学证据很少。我们分析了癌症作为一个次要终点的银杏评价记忆（GEM）研究，最大的随机，双盲，安慰剂对照的临床试验银杏supplementation.Methods的3069 GEM参与者75岁以上的总日期。随机分为每日两次剂量的120毫克银杏提取物（银杏叶提取物761）或安慰剂，并随后为中位数6.1年。我们通过回顾随访期间所有住院报告的入院和出院记录，确定了浸润性癌症的住院情况。使用意向治疗方法，我们比较了分配到治疗组和分配到安慰剂组的参与者之间的癌症住院风险。结果在干预期间，安慰剂组有148例癌症住院，EGb 761组有162例（风险比（HR），1.09; 95%置信区间（CI），0.87-1.36; p = 0.46）。在分析的特定部位癌症中，我们观察到乳腺癌的风险增加，（HR，2.15; 95%CI，0.97-4.80; p = 0.06）和结直肠癌（HR，1.62; 95%CI，0.92-2.87; p = 0.10）癌症，前列腺癌风险降低（HR，0.71; 95%CI，0.43-1.17; p = 0.18）.结论总的来说，这些结果不支持经常使用银杏叶降低癌症风险的假设。版权所有（C）2010约翰威利父子有限公司
Purpose Evidence from in vitro and in vivo studies suggests that Ginkgo biloba has cancer chemopreventive properties, but epidemiological evidence is sparse. We analyzed cancer as a secondary endpoint in the Ginkgo Evaluation of Memory (GEM) Study, the largest randomized, double-blind, placebo-controlled clinical trial of Ginkgo supplementation to date.Methods A total of 3069 GEM participants 75+ years of age were randomized to twice-daily doses of either 120 mg Ginkgo extract (EGb 761) or placebo and followed for a median 6.1 years. We identified hospitalizations for invasive cancer by reviewing hospital admission and discharge records for all reported hospitalizations over follow-up. Using an intention-to-treat approach, we compared the risk of cancer hospitalization between participants assigned to treatment and those assigned to placebo.Results During the intervention, there were 148 cancer hospitalizations in the placebo group and 162 in the EGb 761 group (Hazard ratio (HR), 1.09; 95% confidence interval (CI), 0.87-1.36; p = 0.46). Among the site-specific cancers analyzed, we observed an increased risk of breast (HR, 2.15; 95%CI, 0.97-4.80; p = 0.06) and colorectal (HR, 1.62; 95%CI, 0.92-2.87; p = 0.10) cancer, and a reduced risk of prostate cancer (HR, 0.71; 95%CI, 0.43-1.17; p = 0.18).Conclusions Overall, these results do not support the hypothesis that regular use of Ginkgo biloba reduces the risk of cancer. Copyright (C) 2010 John Wiley & Sons, Ltd.